Vivos Therapeutics (NASDAQ: VVOS) reported Q1 EPS of ($0.52), $0.07 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $5.14 million versus the consensus estimate of $7.5 million.

For earnings history and earnings-related data on Vivos Therapeutics (VVOS) click here.